Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models

Citations Over TimeTop 10% of 2022 papers

Abstract

Immunotherapy using chimeric antigen receptor (CAR) T cells is a rapidly emerging modality that engineers T cells to redirect tumor-specific cytotoxicity. CAR T cells have been well characterized for their efficacy against B cell malignancies, and rigorously studied in other types of tumors. Preclinical evaluation of CAR T cell function, including direct tumor killing, cytokine production, and memory responses, is crucial to the development and optimization of CAR T cell therapies. Such comprehensive examinations are usually performed in different types of models. Model establishment should focus on key challenges in the clinical setting and the capability to generate reliable data to indicate CAR T cell therapeutic potency in the clinic. Further, modeling the interaction between CAR T cells and tumor microenvironment provides additional insight for the future endeavors to enhance efficacy, especially against solid tumors. This review will summarize both in vitro and in vivo models for CAR T cell functional evaluation, including how they have evolved with the needs of CAR T cell research, the information they can provide for preclinical assessment of CAR T cell products, and recent technology advances to test CAR T cells in more clinically relevant models.

Related Papers

• → Immunotherapy and tumor microenvironment(2015)303 cited
• → Role of the tumor immune microenvironment in tumor immunotherapy (Review)(2021)41 cited
• → CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements(2022)2 cited
• → The present situation and prospect of CAR-T cellular immunotherapy(2020)
• → Current status and problems of chimeric antigen receptor T cell immunotherapy in treatment of hematological malignancies(2020)